were both blinded to the treatment. The agents were administered to the subjects on the morning of surgery 1 hour (+/-15 minutes) prior to the procedure. A data sheet with a urine color scale was used intraoperatively as a grading system by the surgeons to grade the color of the urine jet and to evaluate the strength of the urine jet. RESULTS: The Cochran-Mantel-Haenszel for ordinal outcomes was used to compute the appropriate Chi-square test for equivalence between color intensity of the three groups. The study found comparable results for urine color intensity for both vitamin B riboflavin and pyridium and overall the results showed that both agents produced a strong urine jet with moderate color intensity in 75% of cases for vitamin B riboflavin and 80% of cases for pyridium as evaluated by the surgeons at the time of cystoscopy. Renal function influenced the results. Patients with creatinine levels greater than 0.7 were found to have bright colored urine jets 75% of the time based on surgeon evaluation with the urine color grading scale while patients with creatinine levels less than 0.7 were found to have light/no colored urine 35% of the time. CONCLUSION: Vitamin B riboflavin is an appropriate comparable oral agent to pyridium for producing urine staining and evaluating the patency of ureteral jets at the time of intraoperative cystoscopy. Renal function can impact the evaluation of urine color. Patients with lower creatinine levels and higher functioning kidneys may clear the oral agents more quickly in the urine which may in some cases lessen the intensity of the urine jet and cause the urine to have a lighter color. However, patients with lower functioning kidneys as indicated by higher creatinine levels may have more concentrated urine which may cause urine jets to have brighter colored urine in some cases. One must account for renal function when using oral agents for evaluation of ureteral patency.
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28 Incidence and predictors of explantation of sacral neuromodulator in a single urban medical center OBJECTIVES: Sacral neuromodulation has been used for urinary voiding dysfunction and chronic fecal incontinence. The primary goal of this study is to investigate the incidence and predictors of explantation of sacral neuromodulator at an Urban Medical Center.
MATERIALS AND METHODS:
A retrospective chart review of all patients 20 years old who underwent sacral neurostimulator implantation between January 2012 and December 2017 at an Urban Medical Center was performed. Statistical analysis was performed using R version 3.5.1. Continuous measures were expressed as mean and standard deviation (SD) or median and interquartile range (IQR). Univariable and multivariable Cox Proportional-Hazards regression was used to determine the association between time to explantation and demographic and clinical variables. Explantation free survival was estimated using the Kaplan-Meier Method. RESULTS: A total of 109 patients who received sacral neurostimulator were analyzed with a median follow-up of 9 months (IQR: 3, 30). The main indication for sacral neuromodulation for this study was fecal incontinence (88%). Eighteen (16.5%) patients underwent explantation. The incidence of explantation was 0.009 per personyear (95% CI: 0.006, 0.015). The main reasons for explantation were due to loss of efficiency (9/18) and no benefit after Stage 1 (3/18). Among those explanted, the median time to explantation was 11 months (IRQ: 0.81-26.5). In univariable analyses, only age (p ¼0.049) and staged procedure status (p ¼0.004) were significantly associated with explantation [ Table 1 ]. Patients in the non-staged groups had a significantly higher probability of being explantationfree compared to those in the staged group [ Figure 1 ]. In multivariable analyses, adjusting for age, the hazard of explantation in the staged group was 4.44 times higher compared to the non-staged group (95% CI: 1.38-14.24; p ¼0.012). After adjusting for procedure type, age was not significantly associated with explantation (p¼0.39). Within 4 months, 44% (8/18) of patients with explantation had the stimulator re-implanted. CONCLUSION: Sacral neuromodulation is an effective treatment option. However, explantation can occur mainly due to loss of efficacy. It is an interesting finding that after adjusting for age, the hazard of explantation was 4.44 times higher in the staged group, compared to the non-staged group. Further prospective studies are warranted. OBJECTIVES: To present a rare case of ovotesticular disorder of sexual development (OT-DSD).
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MATERIALS AND METHODS:
We present a 21-year-old patient with gynandromorphic genitalia and breast development diagnosed with 46,XX OT-DSD. He was raised as a male and desired correction of his feminized anatomic features. A computer tomography of the abdomen and pelvis demonstrated normal kidneys, bilateral ureters, a uterine horn, an intra-abdominal gonad on the left, a descended gonad on the right and a structure consistent with a vagina. On physical examination, the patient demonstrated the presence of bilateral, symmetrical breasts and the external genitalia showed the presence of a 7 cm long penile-like structure that was immobile and adherent to the ventral aspect of a clitoral hood. A small, presumed testis within the scrotum was noted only on the right side, while the testis and scrotum were absent on the left. A perineal opening appearing to be the vaginal introitus was ultimately identified as the urethra on further investigation. Intra-operative findings included a small, boggy uterine horn and a left gonad which appeared to be a normal ovary with a dilated left fallopian tube. Bilateral ureters with efflux were identified in the normal anatomical position leading to a normal appearing bladder. In accordance with the patient's wishes, an abdominal hysterectomy, left salpingo-oophorectomy, right trans-scrotal testicular biopsies and bilateral simple mastectomy were performed. RESULTS: Histopathologic examination of the excised gonads was performed at our institution. Examination of the right trans-scrotal biopsy confirmed testicular tissue. Examination of the left-sided gonad was consistent with an ovarian tissue. Traditional cytogenetic analysis revealed 46, XX. Six months after the initial surgery, the patient underwent the second stage of gender confirmation surgery. Penile reconstructive surgery and metoidioplasty were performed by dividing the skin of the phallus/clitoris from the underlying cavernous body. The reconstruction of the penis was completed by advancing another skin flap from the left labia majora. The patient's 6-month follow-up demonstrated an uncomplicated post-operative course, living as a male. CONCLUSION: For many children with ambiguous genitalia in the developing world, it is not until puberty before problems associated with feminization become apparent. Very often, as in our case, multiple surgical procedures are necessary to fulfill the gender choice of the patient. Most patients would prefer to live as a male because of cultural bias. However, it is rare that a patient in the developing world who has been feminized or masculinized during their post-pubescent years actually find surgeons to perform gender assignment surgery. This is usually due to the absence of knowledgeable medical resources and the prohibitive cost.
